STOCK TITAN

Purple Biotech Reports First Quarter 2022 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Purple Biotech, listed as PPBT, reported Q1 2022 financial results, highlighting a net loss of $7.3 million, or $0.41 per ADS, compared to a loss of $6.6 million, or $0.38 per ADS, in Q1 2021. Research and Development expenses increased by 22% to $6.0 million, primarily due to CMC costs. However, Sales, General, and Administrative expenses decreased to $1.4 million. The company had $42.2 million in cash and equivalents at the end of Q1. Clinical advancements include completing enrollment for NT219 and initiating expansion arms for CM24.

Positive
  • Company has $42.2 million in cash, positioning for future growth.
  • Completion of enrollment in the Phase 1/2 trial for NT219.
Negative
  • Net loss increased to $7.3 million, a rise of $0.8 million year-over-year.
  • Operating loss increased by 12% to $7.3 million from $6.5 million in Q1 2021.

REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced financial results for the first quarter ended March 31, 2022.

“We were focused in the clinical advancement of our promising first in class oncology drug candidates during this quarter,” said Gil Efron, President and Chief Financial Officer of Purple Biotech. “For NT219, we completed enrollment in the fourth dose level of the monotherapy arm of the ongoing Phase 1/2 clinical trial and will soon start the last dose level planned in the dose escalation part of the monotherapy arm. For CM24, we will soon initiate the expansion arms of the study. We had $42.2 million in cash, cash equivalent, short and long-term deposits at the end of the first quarter this year and we are well positioned to execute our plans.”

Financial Results for the Three Months Ended March 31, 2022
Research and Development Expenses were $6.0 million, an increase of $1.1 million, or 22%, compared to $4.9 million in the same period of 2021. The increase was mainly due to CMC expenses in support of our clinical studies.

Sales, General and Administrative Expenses were $1.4 million, compared to $1.7 million in the same period of 2021, a decrease of $0.3 million. The decrease was mainly due to a decrease in employee equity-based compensation (ESOP) costs.

Operating Loss from continuing operations was $7.3 million, an increase of $0.8 million, or 12%, compared to $6.5 million in the same period of 2021.

On a non-IFRS basis (as reconciled below), adjusted operating loss was $7.0 million, an increase of $1.2 million, compared to $5.8 million in the same period of 2021, mainly due to a decrease in Selling, General and Administrative expenses offset by an increase in R&D expenses.

Net Loss for the first three months ended March 31, 2022 was $7.3 million, or $0.41 per basic and diluted ADS, compared to a net loss of $6.6 million, or $0.38 per basic and diluted ADS, in the same period of 2021. The increase in net loss was mainly due to an increase of $0.8 million in operating expenses. Adjusted net loss for the first three months ended March 31, 2022 was $7.0 million, an increase from $5.8 million in the first three months ended March 31, 2021.

During the three months ended March 31, 2022, the Company sold, under the Open Market Sale Agreementsm with Jefferies LLC, approximately 59 thousand ADSs, at an average price of $3.932 per ADS. Net proceeds to the Company, were approximately $0.22 million, net of issuance expenses.

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study, followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in addition to nab-paclitaxel (ABRAXANE®) or 5-fluorouracil and liposomal irinotecan. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2021 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

Company Contact:

Gil Efron

President & Chief Financial Officer

IR@purple-biotech.com


Purple Biotech Ltd.   
    
Consolidated Unaudited Statements of Financial Position as of: 
    
 March 31, December 31,  
 2022 2021  
 USD thousands USD thousands  
    
      
Assets     
Cash and cash equivalents23,537 10,890  
Short term deposits16,010 36,310  
Other current assets2,352 1,273  
      
Total current assets41,899 48,473  
      
Non-current assets     
Other investments187 187  
Right to use assets581 619  
Fixed assets, net286 277  
Long term deposits2,657 160  
Intangible assets20,684 20,482  
      
Total assets66,294 70,198  
      
Liabilities     
Lease liability – short term199 199  
Accounts payable1,651 1,473  
Other payables5,338 2,578  
      
Total current liabilities7,188 4,250  
      
Non-current liabilities     
      
Lease liability495 550  
Post-employment benefit liabilities292 292  
      
Total non–current liabilities787 842  
      
Equity     
Share capital, no par value- -  
Share premium124,356 123,951  
Receipts on account of warrants28,017 28,017  
Capital reserve for share-based payments8,987 8,862  
Capital reserve from transactions with related parties761 761  
Capital reserve from transactions with non-controlling     
interest(859)(859) 
Accumulated loss(103,202)(95,905) 
      
Equity attributable to owners of the Company58,060 64,827  
Non-controlling interests259 279  
Total equity58,319 65,106  
      
Total liabilities and equity66,294 70,198  

 

Purple Biotech Ltd.  
   
Consolidated Unaudited Statement of Operations for the three months ended March 31, 2022 
   
   
 March 31, March 31, 
 2022 2021 
 USD thousands USD thousands 
     
Research and development expenses5,952 4,874 
Sales, general and administrative expenses1,379 1,657 
     
Operating loss7,331 6,531 
     
     
Finance expenses41 20 
Finance income(56)(118)
     
Finance income, net(15)(98)
     
Loss for the periodfrom continuing operations7,316 6,433 
     
     
Loss for the periodfrom discontinued operation- 136 
     
Loss attributable to:    
Owners of the Company7,297 6,547 
Non-controlling interests19 22 
 7,316 6,569 
     
Loss per share data    
Continuing operations    
Basic and diluted loss per ADS – USD0.41 0.37 
     
Number of ADSs used in calculating basic and diluted loss per ADS17,812,673 17,377,241 
     
Discontinued operation    
Basic and diluted loss per ADS – USD- 0.01 
Number of ADSs used in calculating basic and diluted loss per ADS- 17,377,241 
     


Reconciliation of Adjusted Operating Loss  
    
    
 March 31, March 31,  
 2022 2021  
 USD thousands USD thousands  
      
Operating loss for the period7,331 6,531  
Less ESOP expenses(309)(710) 
      
 7,022 5,821  
      
      
Reconciliation of Adjusted Net Loss     
      
 March 31, March 31,  
 2022 2021  
 USD thousands USD thousands  
      
Net loss for the period7,316 6,569  
Less ESOP expenses(309)(710) 
      
 7,007 5,859  


Consolidated Unaudited Statements of Cash Flow      
      
  For the period ended    
 
  March 31,   
 
    2022  2021 
  USD
thousands
 USD
thousands 
 
      
Cash flows from operating activities from continuing operation:     
Loss for the period from continuing operations (7,316)(6,433)
      
Adjustments:     
Depreciation 51 46 
Finance income, net (15)(98)
Share-based payments 309 710 
      
  (6,971)(5,775)
      
Changes in assets and liabilities:     
Changes in trade receivables and other current assets (1,134)(469)
Changes in accounts payable 173 171 
Changes in other payables 2,732 2,750 
Changes in post-employment benefit liabilities - - 
      
  1,771 2,452 
      
Net cash used in operating activities from continuing operations (5,200)(3,323)
      
Cash flows from investing activities from continuing operations:     
Acquisition of intangible asset (203) - 
Decrease in deposits 17,800 1,300 
Interest received 133 40 
Acquisition of fixed assets (14)(27)
      
Net cash provided by investing activities from continuing operations 17,716 1,313 
      
Cash flows from financing activities from continuing operations:     
Proceeds from issuance of ADSs 230 - 
ADS issuance expenses paid (9)- 
Proceeds from issuance of warrants - 1,200 
Repayment of lease liability (42)(36)
Interest paid (17)(19)
      
Net cash provided by financing activities from continuing operations 162 1,145 
      


  For the three months ended   
  March 31,   
  2022    2021 
        
  USD
thousands
   USD
thousands
 
Cash flows in respect of discontinued operation as follows:       
        
Net cash from (used in) operating activities -   (155)
Net cash from investing activities -   - 
Net cash from financing activities -   - 
      
Net cash from (used in) discontinued operation -   (155
      
Net increase (decrease) in cash and cash equivalents 12,678   (1,020)
Cash and cash equivalents at the beginning of the period 10,890   11,247 
Effect of translation adjustments on cash and equivalents (31)  (32)
      
Cash and cash equivalents at end of the period 23,537   10,195 
      

FAQ

What were Purple Biotech's Q1 2022 financial results?

Purple Biotech reported a net loss of $7.3 million, or $0.41 per ADS, for Q1 2022, compared to a net loss of $6.6 million in Q1 2021.

How did research and development expenses change in Q1 2022 for PPBT?

Research and Development expenses increased by 22% to $6.0 million in Q1 2022, mainly due to CMC expenses.

What is the current cash position of Purple Biotech?

As of March 31, 2022, Purple Biotech had $42.2 million in cash and cash equivalents.

What clinical developments did Purple Biotech achieve in Q1 2022?

The company completed enrollment for the fourth dose level of NT219 and will soon initiate expansion arms for CM24.

Purple Biotech Ltd. American Depositary Shares

NASDAQ:PPBT

PPBT Rankings

PPBT Latest News

PPBT Stock Data

8.42M
2.53M
2.87%
9.33%
1.25%
Biotechnology
Healthcare
Link
United States of America
Rehovot